
VistaGen Therapeutics VTGN
€ 0.23
0.21%
Land |
|
IPO-Jahr |
- |
Branche |
Pharmaeinzelhändler |
Börse |
NASDAQ GLOBAL |
Anteile |
38.1 M |
Marktkapitalisierung |
$ 9.9 M |
EBITDA (LTM) |
$ -71.9 M |
P/E (LTM) |
-0.125654 |
P/S (LTM) |
8.24706 |
EPS (LTM) |
-1.91 |
Andere Aktien der Branche "Pharmaeinzelhändler"
| Name | Preis | % 24h | Marktkapitalisierung | Börse | Land | |
|---|---|---|---|---|---|---|
|
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | ||
|
Landos Biopharma
LABP
|
- | 0.58 % | $ 144 M | Nasdaq Global Market | ||
|
PhaseBio Pharmaceuticals
PHAS
|
- | 7.4 % | $ 6.29 M | Nasdaq Global Market | ||
|
Provention Bio
PRVB
|
- | - | $ 2.37 B | Nasdaq Global Select Market | ||
|
Poseida Therapeutics
PSTX
|
- | - | $ 857 M | Nasdaq Global Select Market | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
Lumos Pharma
LUMO
|
- | - | $ 35.3 M | Nasdaq Global Select Market | ||
|
Stealth BioTherapeutics Corp
MITO
|
- | - | $ 23.9 M | Nasdaq Global Select Market | ||
|
Satsuma Pharmaceuticals
STSA
|
- | -0.9 % | $ 36.5 M | Nasdaq Global Market | ||
|
89bio
ETNB
|
- | - | $ 1.55 B | Nasdaq Global Market | ||
|
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | Nasdaq Global Select Market | ||
|
SpringWorks Therapeutics
SWTX
|
- | - | $ 3.48 B | Nasdaq Global Select Market,SPB | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
OncoSec Medical Incorporated
ONCS
|
- | 31.87 % | $ 1.61 M | Nasdaq Global Select Market | ||
|
Y-mAbs Therapeutics
YMAB
|
- | - | $ 382 M | Nasdaq Global Select Market,SPB | ||
|
Oncternal Therapeutics
ONCT
|
- | -24.12 % | $ 1.56 M | Nasdaq Capital Market | ||
|
Navidea Biopharmaceuticals
NAVB
|
- | -2.99 % | $ 2.47 M | NYSE American | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
BELLUS Health
BLU
|
- | - | $ 2.47 B | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Intra-Cellular Therapies
ITCI
|
- | - | $ 13.6 B | Nasdaq Global Select Market,SPB | ||
|
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | ||
|
ContraFect Corporation
CFRX
|
- | -5.16 % | $ 5.39 M | Nasdaq Capital Market | ||
|
Turning Point Therapeutics
TPTX
|
- | -0.13 % | $ 3.73 B | Nasdaq Global Select Market,SPB | ||
|
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | ||
|
Forward Pharma A/S
FWP
|
- | -0.75 % | $ 18.7 M | Nasdaq Capital Market | ||
|
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Nasdaq Global Market | ||
|
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | ||
|
Marinus Pharmaceuticals
MRNS
|
- | - | $ 29.6 M | Nasdaq Global Select Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Seagen
SGEN
|
- | - | $ 42.2 B | Nasdaq Global Select Market,SPB | ||
|
Sigilon Therapeutics
SGTX
|
- | - | $ 728 M | Nasdaq Global Select Market | ||
|
Rubius Therapeutics
RUBY
|
- | -33.55 % | $ 7.81 M | Nasdaq Global Select Market | ||
|
TRACON Pharmaceuticals
TCON
|
- | -1.38 % | $ 46.8 M | Nasdaq Capital Market | ||
|
Revance Therapeutics
RVNC
|
- | - | $ 309 M | Nasdaq Global Select Market | ||
|
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market | ||
|
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | ||
|
Forma Therapeutics Holdings
FMTX
|
- | - | $ 958 M | Nasdaq Global Market | ||
|
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | ||
|
Blueprint Medicines Corporation
BPMC
|
- | - | $ 8.14 B | Nasdaq Global Select Market,SPB | ||
|
Paratek Pharmaceuticals
PRTK
|
- | - | $ 121 M | Nasdaq Global Market | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
- | -14.27 % | $ 1.7 M | Nasdaq Global Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market |